Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


14 diciembre 2015

Optimism associated with reduced cardiac readmission after acute coronary syndrome

Cardiovascular News

Jeff C Huffman (Harvard Medical School, Boston, USA) and others report in Circulation Cardiovascular Quality Outcomes that optimism after acute coronary syndrome is an independent predictor of both increased physical activity and reduced cardiac readmission. However, gratitude does not appear to affect these outcomes.

16 diciembre 2015

CE mark for Svelte Medical’s sirolimus-eluting coronary stent-on-a-wire integrated delivery system

Cardiovascular News

Svelte Medical Systems has received the CE mark for its Slender sirolimus-eluting coronary stent-on-a-wire integrated delivery system for the treatment of coronary artery disease. The company claims that the device is the world’s lowest profile drug-eluting stent, reducing the catheter size necessary to perform percutaneous coronary intervention (PCI) and facilitating transradial intervention in more patients.

09 febrero 2016

US Medicare to cover Boston Scientific Watchman left atrial appendage closure device

Cardiovascular News

The US Centers for Medicare and Medicaid Services (CMS) are to cover percutaneous left atrial appendage closure (LAAC) therapy under specific criteria, as outlined in the agency’s final National Coverage Determination (NCD). This decision, effective immediately, provides consistent and uniform access to the Watchman LAAC Device as a non-pharmacological treatment option for stroke risk reduction for appropriate Medicare beneficiaries.

27 enero 2016

Non-transfemoral access is strongly associated with post-TAVI delirium

Cardiovascular News

Masieh Abawi (Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands) and others report in JACC Cardiovascular Interventions that about 13% of patients develop postoperative delirium after undergoing transcatheter aortic valve implantation (TAVI). Furthermore, they write that non-transfemoral access is strongly associated with the condition.

11 diciembre 2015

US cardiovascular societies publish joint expert consensus on left atrial appendage occlusion requirements

Cardiovascular News

The Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC) and the Heart Rhythm Society (HRS) have published a joint document providing recommendations—for institutions and interested physicians—for the establishment and maintenance of left atrial appendage occlusion programmes performing left atrial appendage closure.

11 diciembre 2015

Edward Lifesciences announces further investments into mitral valve therapies

Cardiovascular News

Edwards Lifesciences outlined its strategy for longer term growth, providing an update on its technology pipeline and share its financial guidance for 2016, during its annual investor conference today. It announced a structured investment in Harpoon Medical, which is pioneering a beating-heart, transcatheter therapy for minimally invasive surgical repair of a degenerative mitral valve.

27 noviembre 2015

New delivery sheath may enable more patients to undergo transfemoral TAVI

Cardiovascular News

Walid K Abu Shaleh (Houston Methodist DeBakey Heart & Vascular Centre, Department of Cardiovascular Surgery, Houston Methodist Hospital, Houston, USA) and others report in Catheterization and Cardiovascular Interventions that a new balloon-expandable, re-collapsible (BERC) sheath (Solopath, Terumo) may “considerably expand” the population suitable for transcatheter aortic valve implantation (TAVI) via the transfemoral approach.

26 noviembre 2015

First patient undergoes mitral replacement with NaviGate Cardiac Structures’ mitral valve stent

Cardiovascular News

NaviGate Cardiac Structures has revealed that the first-in-human implant of its catheter-guided, mitral-valve stent into a beating heart was performed successfully in a 53-year-old male patient presenting with severe mitral regurgitation. The interventional team was led by Cristián Baeza Prieto (San Borja Arriarán Hospital in Santiago, Chile); the patient is reported to be “thriving” at four weeks post-procedure.

20 noviembre 2015

Next-generation Watchman approved for use in Europe

Cardiovascular News

The next-generation Watchman left atrial appendage closure device (Watchman FLX) has received CE mark approval and the first implants of the Boston Scientific device have taken place in Germany, the Czech Republic and in Slovenia, commencing limited market release.

19 noviembre 2015

Anticoagulation with heparin “should remain standard of care” during TAVI procedures

Cardiovascular News

George Dangas (New York, USA) and others report in JACC: Cardiovascular Interventions that heparin should continue to be the first-line anticoagulant for transcatheter aortic valve implantation (TAVI) procedures because it is not associated with a significantly increased risk of bleeding compared with bivalirudin (Angiomax, The Medicines Company).

12 noviembre 2015

An interventional cardiologist’s view on left atrial appendage closure

Cardiovascular News

Martin W Bergmann is an interventional cardiologist working in Germany, who performs percutaneous left atrial appendage (LAA) closure procedures. He explores why there is still a need for such procedures even in the era of novel oral anticoagulants and reviews the vital role of the interventional cardiologist in heart teams involved in LAA closure.

03 noviembre 2015

Low baseline albumin associated with increased all-cause mortality after TAVI

Cardiovascular News

Andrada Bogdan (Leviev Heart Centre, Sheba Medical Centre, Tel Hashomer, Israel) and others report in EuroIntervention that baseline albumin could be used as a “simple objective tool to assess frailty” as part of risk stratification in patients undergoing transcatheter aortic valve implantation (TAVI). They found that low baseline albumin (≤4g/dl) in TAVI patients was associated with a four-fold increase in all-cause mortality at one year and a two-fold increase in all-cause mortality at two years.

28 octubre 2015

Direct Flow Medical appoints new co-principal investigator for US SALUS pivotal trial

Cardiovascular News

Direct Flow Medical has appointed D Scott Lim as national co-principal investigator for the SALUS pivotal trial. Lim is currently a medical director of the Bon Secours Virginia Advanced Cardiac Valve Center, and is an associate professor of medicine and paediatrics for the Advanced Cardiac Valve Center at the University Of Virginia, USA. He joins co-principal investigator Isaac George, surgical director of transcatheter therapies for the Columbia Heart Valve Center at Columbia University Medical Center.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.